ARPA Bio

We are dedicated to shaping the future of Alzheimer's disease treatment through innovative approaches that promise hope for early therapeutic intervention.

 

We are a Swiss, preclinical stage startup company, dedicated to developing innovative diagnostic tools and therapies for the treatment of neurodegenerative disorders. At ARPA Bio, we translate our scientific insights into highly selective and targeted treatments. Our research supports a novel, unparalleled approach for targeting early, pathological amyloid-beta (Aβ) species during the insidious phase of the disease and prior to the appearance of neurotoxic entities in the brain, which is why we clearly distinguish from the current clinical therapies for Alzheimer’s disease.

currently offline...